Research intelligence // editorial
About Medicinal Sermorelin
A cited, evidence-graded brief on the GHRH(1-29) secretagogue literature — what the studies measured, graded honestly.
What this site is
Medicinal Sermorelin is an intelligence brief on the peer-reviewed research into sermorelin — the GHRH(1-29) growth-hormone secretagogue. It is not a clinic and employs no clinicians; it gives no medical advice, and it manufactures, sells, and distributes nothing. Its work is to read the published science and grade it honestly, each figure cited to its source.
The site reads the literature the way a research-intelligence brief reads a record: the headline finding first, the supporting study disclosed beneath, and the evidence graded — strong where the data is strong (pediatric growth hormone deficiency), limited where it thins out (long-term adult anti-aging use). Every quantitative claim on the site carries a citation to a named, dated study.
What the name means
The word "medicinal" in this domain is editorial framing, not a service claim. It signals the register we write in — a sober, clinical-intelligence reading of the evidence — not the existence of a clinic, a pharmacy, or a prescription service. We do not diagnose, treat, consult, or dispense. Sermorelin's regulatory history is part of the record we cover: it was a formerly FDA-approved prescription drug for growth hormone deficiency in children, withdrawn from the US market in 2008 for commercial reasons, and is now prepared by compounding pharmacies as a Category 1 503A bulk substance. We report that status; we are not part of it.
How we handle the evidence
We lead with what was measured and attribute it afterward. We distinguish carefully between findings for sermorelin itself and findings for related analogs such as tesamorelin or CJC-1295, because conflating them is the most common error in popular summaries. We flag the gaps as prominently as the results — the limited long-term adult data, the theoretical oncologic consideration of chronically raising GH and IGF-1, and the fact that anti-aging marketing outpaces the evidence. Where the research is computational or hypothesis-generating, we say so rather than dressing it as clinical proof. The goal is a digest a careful reader can trust and verify.